Liu Hongxiang, Song Junmin, Yang Zhen, Zhang Xiefu
Departments of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450012, P.R. China.
Exp Ther Med. 2013 Oct;6(4):953-956. doi: 10.3892/etm.2013.1247. Epub 2013 Aug 5.
The aim of this study was to investigate the effects of cytokine-induced killer (CIK) cell treatment combined with FOLFOX4 on the recurrence and survival rates of patients suffering from gastric cancer following surgery. A total of 98 patients with gastric cancer, who were surgically treated from June 2010 to June 2012, were divided into two groups: 47 patients, who underwent FOLFOX4 treatment alone, served as the control group, while the remaining 51 patients received FOLFOX4 in combination with CIK cell immunotherapy and served as the observation group. The immune functions, recurrence and survival rates were estimated and compared between the two groups. No significant differences were observed between the immune functions of the patients prior to treatment compared with the functions following treatment (P>0.05). However, the immune functions of the patients were improved following FOLFOX4 treatment in combination with CIK cell immunotherapy compared with the functions of the patients who received FOLFOX4 treatment alone (P<0.05). The gastric cancer recurrence rates of the patients in the observation group were significantly lower compared with those of the patients in the control group (5.9 versus 25.5, 17.6 versus 36.2 and 23.5 versus 48.9% after 1, 2 and 3 years, respectively; P<0.05). In addition, the survival rates of the patients with gastric cancer in the observation group were significantly enhanced compared with those of the control group, as assessed by log-rank test analysis (98.0 versus 93.6, 92.2 versus 78.7 and 72.5 versus 59.6% after 1, 2 and 3 years, respectively; P<0.05). It may be concluded that FOLFOX4 combined with CIK cell treatment has significant benefits for patients suffering from gastric cancer, compared with FOLFOX4 treatment alone.
本研究旨在探讨细胞因子诱导的杀伤（CIK）细胞治疗联合FOLFOX4对胃癌患者术后复发率和生存率的影响。选取2010年6月至2012年6月接受手术治疗的98例胃癌患者，分为两组：47例仅接受FOLFOX4治疗的患者作为对照组，其余51例接受FOLFOX4联合CIK细胞免疫治疗的患者作为观察组。评估并比较两组患者的免疫功能、复发率和生存率。治疗前患者的免疫功能与治疗后相比无显著差异（P>0.05）。然而，与仅接受FOLFOX4治疗的患者相比，FOLFOX4联合CIK细胞免疫治疗后患者的免疫功能得到改善（P<0.05）。观察组患者的胃癌复发率显著低于对照组（1年、2年和3年后分别为5.9%对25.5%、17.6%对36.2%和23.5%对48.9%；P<0.05）。此外，通过对数秩检验分析评估发现，观察组胃癌患者的生存率显著高于对照组（1年、2年和3年后分别为98.0%对93.6%、92.2%对78.7%和72.5%对59.6%；P<0.05）。可以得出结论，与单独使用FOLFOX4治疗相比，FOLFOX4联合CIK细胞治疗对胃癌患者有显著益处。
